KZIA

KAZIA THERAPEUTICS LTD KZIA

NasdaqMid CapHealthcare

13F Pro quality score

Rank #2,602 of 2,925

Why it scores 26Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$42.0K

Quarter to Jun 30

Net income

$-20.70M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$50.73M total
Boxer Capital Management, LLC
$7.88MNew
FLPUTNAM INVESTMENT MANAGEMENT CO
$5.84M+191.3%
Bleichroeder LP
$5.63M0.0%
Ikarian Capital, LLC
$5.58MNew
Dauntless Investment Group, LLC
$4.99M+343.7%
Stonepine Capital Management, LLC
$4.86M0.0%
Point72 Asset Management, L.P.
$2.30M+0.1%
Ensign Peak Advisors, Inc
$1.56MNew
MILLENNIUM MANAGEMENT LLC
$1.43MNew
UBS Group AG
$1.14M+482.0%
J. Goldman & Co LP
$964.4KNew
ADAR1 Capital Management, LLC
$866.6KNew
JANE STREET GROUP, LLC
$804.5KNew
BARCLAYS PLC
$802.5K+137.5%
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$712.7KNew
COOPERMAN LEON G
$704.0KNew
Westside Investment Management, Inc.
$670.0K-5.6%
MORGAN STANLEY
$656.2K+4560.6%
MARSHALL WACE, LLP
$622.8KNew
XTX Topco Ltd
$439.1KNew
BNP PARIBAS FINANCIAL MARKETS
$423.7K+2683.5%
CITADEL ADVISORS LLC
$401.4KNew
RAYMOND JAMES FINANCIAL INC
$318.2K+43.5%
Sequoia Financial Advisors, LLC
$281.6K-66.7%
Engineers Gate Manager LP
$210.8KNew
See all 37 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

FY 2025
EDGAR

Net Income

FY 2025
EDGAR

EPS (Diluted)

FY 2025
EDGAR

Loading ratio trend…

KZIA key financials by period

Reported revenue, net income and operating margin by fiscal year, from KAZIA THERAPEUTICS LTD's annual filings on SEC EDGAR.

KAZIA THERAPEUTICS LTD reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$42.0K$-20.7M—
FY 2024$2.3M$-26.8M—
FY 2021$15.2M$-8.4M-58.6%
FY 2018$119.0K$-6.0M—
FY 2017$249.0K$-10.7M—
FY 2016$406.0K$-12.1M—
Source: KZIA filings on SEC EDGAR →

KZIA insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About KAZIA THERAPEUTICS LTD (KZIA): stock profile, AI score and financials

KAZIA THERAPEUTICS LTD (KZIA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KZIA at 26.0/100 on a composite quality score built from its SEC filings, placing it at rank #2,602 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (FY 2025), KAZIA THERAPEUTICS LTD reports quarterly revenue of $42.0K, net income of $-20.7M. Top institutional holders of KZIA by reported 13-F value include Boxer Capital Management, FLPUTNAM INVESTMENT MANAGEMENT, Bleichroeder, based on the most recent SEC filings. KZIA trades on the Nasdaq exchange and files with the SEC under CIK 1075880. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KZIA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for KAZIA THERAPEUTICS LTD directly from SEC EDGAR.

SEC EDGAR: CIK 1075880 →